Iron replacement in inflammatory bowel diseases: an evolving scenario
- 12 Downloads
Iron deficiency anemia (IDA) represents the most common extra-intestinal complication in patients with chronic inflammatory bowel diseases (IBD) [1, 2]. Iron deficiency (ID), even without anemia, negatively impacts on patients’ quality of life, and is associated with the development of various comorbidities and an increased risk of hospitalization . Thus, timely correction of ID, before anemia develops, is a major goal in IBD patients.
Historically, oral iron salts (typically ferrous sulfate) have been generally considered the standard first-line therapy for IDA, especially when anemia is mild and/or paucisymptomatic. The recommended daily dose for adults with ID is 100 to 200 mg of elemental iron. Although oral iron salts are safe, relatively inexpensive and widely accessible, their use is associated with several gastrointestinal adverse effects (AEs), such as nausea, constipation, diarrhea, and abdominal pain that can arise in up to 30–70% of patients . Such AEs are...
Compliance with ethical standards
Conflict of interest
FB and GM declare that they have no conflict of interest. DG declares fees for participation in advisory boards for La Jolla Pharmaceutical, Silence Therapeutics, and Novartis, and has received lecture fees from Vifor Fresenius Medical Pharma.
Statement of human and animal rights
This article does not contain any studies with human participants or animals performed by any of the authors.
- 5.Stein J, Aksan A, Farrag K, Dignass A, Radeke HH (2017) Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice. Expert Opin Pharmacother 18(16):1721–1737. https://doi.org/10.1080/14656566.2017.1391790 CrossRefPubMedGoogle Scholar
- 6.Rampton DS, Goodhand JR, Joshi NM, Karim AB, Koodun Y, Barakat FM, Macken L, Ward DG, Iqbal TH, Epstein J, Fell JM, Sanderson IR (2017) Oral Iron Treatment Response and Predictors in Anaemic Adolescents and Adults with IBD: A Prospective Controlled Open-Label Trial. J Crohns Colitis 11(6):706–715. https://doi.org/10.1093/ecco-jcc/jjw208 PubMedGoogle Scholar
- 9.Jaeggi T, Kortman GA, Moretti D, Chassard C, Holding P, Dostal A, Boekhorst J, Timmerman HM, Swinkels DW, Tjalsma H, Njenga J, Mwangi A, Kvalsvig J, Lacroix C, Zimmermann MB (2015) Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut 64(5):731–742. https://doi.org/10.1136/gutjnl-2014-307720 CrossRefPubMedGoogle Scholar
- 10.Asperti M, Gryzik M, Brilli E, Castagna A, Corbella M, Gottardo R, Girelli D, Tarantino G, Arosio P, Poli M (2018) Sucrosomial((R)) Iron Supplementation in Mice: Effects on Blood Parameters, Hepcidin, and Inflammation. Nutrients 10 (10). doi:10.3390/nu10101349Google Scholar
- 11.Martinelli M, Strisciuglio C, Alessandrella A, Rossi F, Auricchio R, Campostrini N, Girelli D, Nobili B, Staiano A, Perrotta S, Miele E (2016) Serum Hepcidin and Iron Absorption in Paediatric Inflammatory Bowel Disease. J Crohns Colitis 10(5):566–574. https://doi.org/10.1093/ecco-jcc/jjv242 CrossRefPubMedGoogle Scholar
- 16.Dignass AU, Gasche C, Bettenworth D, Birgegard G, Danese S, Gisbert JP, Gomollon F, Iqbal T, Katsanos K, Koutroubakis I, Magro F, Savoye G, Stein J, Vavricka S, Cs European, Colitis O (2015) European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 9(3):211–222. https://doi.org/10.1093/ecco-jcc/jju009 CrossRefPubMedGoogle Scholar
- 17.Gomez-Ramirez S, Brilli E, Tarantino G, Munoz M (2018) Sucrosomial((R)) Iron: A New Generation Iron for Improving Oral Supplementation. Pharmaceuticals (Basel) 11 (4). doi:10.3390/ph11040097Google Scholar
- 20.Gasche C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Buning C, Howaldt S, Stallmach A, Group AS (2015) Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis 21(3):579–588. https://doi.org/10.1097/MIB.0000000000000314 CrossRefGoogle Scholar
- 21.Moretti D, Goede JS, Zeder C, Jiskra M, Chatzinakou V, Tjalsma H, Melse-Boonstra A, Brittenham G, Swinkels DW, Zimmermann MB (2015) Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood 126(17):1981–1989. https://doi.org/10.1182/blood-2015-05-642223 CrossRefPubMedGoogle Scholar
- 22.Stoffel NU, Cercamondi CI, Brittenham G, Zeder C, Geurts-Moespot AJ, Swinkels DW, Moretti D, Zimmermann MB (2017) Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol 4(11):e524–e533. https://doi.org/10.1016/S2352-3026(17)30182-5 CrossRefPubMedGoogle Scholar